Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance's new drug application for pretomanid.

Advocates call on WHO leadership to act immediately and correct specific technical errors in the WHO guidelines for the treatment of drug-resistant TB.

Statement by the Global TB Community Advisory Board to the High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate

Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake.

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.

The WHO, Ministries of Health and Finance, donors, implementers, technical assistance providers, civil society, and communities must work together to ensure rapid implementation.

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.

The TB CAB reiterates its request for Johnson & Johnson to commit to a global price for bedaquiline that is no higher than US$32 per month.